RCUS Stock Overview
A clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Arcus Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.51 |
| 52 Week High | US$20.31 |
| 52 Week Low | US$13.50 |
| Beta | 0.89 |
| 11 Month Change | -14.50% |
| 3 Month Change | -17.98% |
| 1 Year Change | 4.61% |
| 33 Year Change | -70.06% |
| 5 Year Change | 72.94% |
| Change since IPO | -14.65% |
Recent News & Updates
Recent updates
Arcus Biosciences: Advancing On Several Fronts
Oct 29Arcus Biosciences Looks Compelling Ahead Of Key Clinical Oncology Milestones
Sep 23Arcus Biosciences (NYSE:RCUS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Sep 15
Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Lagging The Industry But So Is The Business
Aug 19Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment
May 31Arcus Biosciences: A Preview Of Their Outlook Ahead Of ASCO
May 15Party Time: Brokers Just Made Major Increases To Their Arcus Biosciences, Inc. (NYSE:RCUS) Earnings Forecasts
May 13Here's Why Arcus Biosciences (NYSE:RCUS) Can Manage Its Debt Despite Losing Money
May 10We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth
Mar 20What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You
Feb 23Arcus Biosciences: Trading At Large Discount To Recent Gilead Investment
Feb 22Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Dec 18Arcus Biosciences: Showing There Might Be Something To TIGIT After All
Dec 15Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?
Nov 30Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey
Nov 20Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data
Aug 29Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation
Aug 08Arcus Biosciences: Gilead Partnered TIGIT Pioneer Excites But Frustrates
Jun 15Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk
May 05Arcus Biosciences GAAP EPS of -$0.90 beats by $0.17
Nov 02Shareholder Returns
| RCUS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.7% | -7.5% | -1.2% |
| 1Y | 4.6% | 14.1% | 30.4% |
Return vs Industry: RCUS underperformed the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: RCUS underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| RCUS volatility | |
|---|---|
| RCUS Average Weekly Movement | 7.6% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RCUS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RCUS's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 577 | Terry Rosen | www.arcusbio.com |
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease.
Arcus Biosciences, Inc. Fundamentals Summary
| RCUS fundamental statistics | |
|---|---|
| Market cap | US$1.33b |
| Earnings (TTM) | -US$270.00m |
| Revenue (TTM) | US$263.00m |
5.0x
P/S Ratio-4.9x
P/E RatioIs RCUS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RCUS income statement (TTM) | |
|---|---|
| Revenue | US$263.00m |
| Cost of Revenue | US$440.00m |
| Gross Profit | -US$177.00m |
| Other Expenses | US$93.00m |
| Earnings | -US$270.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.95 |
| Gross Margin | -67.30% |
| Net Profit Margin | -102.66% |
| Debt/Equity Ratio | 12.0% |
How did RCUS perform over the long term?
See historical performance and comparison